<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is characterized by defects in insulin secretion and action and is preceded by impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (IFG) </plain></SENT>
<SENT sid="1" pm="."><plain>The islet <z:mp ids='MP_0000002'>anatomy</z:mp> in IFG and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> reveals an approximately 50 and 65% deficit in beta-cell mass, with increased beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and islet amyloid derived from islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (IAPP) </plain></SENT>
<SENT sid="2" pm="."><plain>Defects in insulin action include both hepatic and extrahepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The relationship between changes in beta-cell mass, beta-cell function, and insulin action leading to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are unresolved, in part because it is not possible to measure beta-cell mass in vivo, and most available animal models do not recapitulate the islet pathology in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>We evaluated the HIP rat, a human IAPP transgenic rat model that develops islet pathology comparable to humans with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, at age 2 months (nondiabetic), 5 months (with IFG), and 10 months (with <z:mp ids='MP_0002055'>diabetes</z:mp>) to prospectively examine the relationship between changes in islet <z:mp ids='MP_0000002'>morphology</z:mp> versus insulin secretion and action </plain></SENT>
<SENT sid="5" pm="."><plain>We report that increased beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and impaired first-phase insulin secretion precede the development of IFG, which coincides with an approximately 50% defect in beta-cell mass and <z:hpo ids='HP_0003674'>onset</z:hpo> of hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> was characterized by approximately 70% deficit in beta-cell mass, progressive hepatic and extrahepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and hyperglucagonemia </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that IAPP-induced beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> causes defects in insulin secretion and beta-cell mass that lead first to hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and IFG and then to extrahepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, hyperglucagonemia, and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that a specific beta-cell defect can recapitulate the metabolic phenotype of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and note that <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> may at least in part be secondary to beta-cell failure </plain></SENT>
</text></document>